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Cathepsins are an essential protease family in all living cells. The cathepsins play an essential roles such as protein catabolism
and protein synthesis. To targeting to various organella and to regulate their activity, the post translational-processing and
modiﬁcation play an important role Cathepsins are translated in polysome as the pre-pro-mature forms. The pre-peptide
is removed cotranslationally and then translocated to Golgi-apparatus and the pro-part is removed and the mature-part is
glycosylated, and the mature-part is targeted into the lysosome mediated by mannose-6-phosphate signal and the mature-part
is bound with their coenzymes. The degradation of the mature-part is started by the limited proteolysis of the ordered nicked
bonds to make hydrophobic peptides. The peptides are incorporated into phagosome or proteasome after ubiquitinated and
are degrade into amino-acids. Cystatins are endogenous inhibitors of cathepsins. Cystatin α which is only located in skin is
phosphorylated at the near C-terminus by protein kinase-C, and the phosphorylate-cystatin α is incorporated into corniﬁed
envelope and conjugated with ﬁlaggrin-ﬁber by transglutaminase to form the linker-ﬁber of skin. The cystatin α is modiﬁed
by glutathione or make their dimmer, and they are inactive. Those modiﬁcations are regulated by the redox-potential by the
glutathione.
1.Introduction
We will introduce recent advances on the study of post-
translational processing, modiﬁcation, and targeting of
cathepsins and cystatins. Almost all the intracellular proteins
are passed through principally similar processes from the
synthesis to their degradation in general. Therefore, I would
like to introduce the general fate of intracellular proteins,
from the post-translational processing, modiﬁcation, and
targeting to the ordered particles. As Figure 1 shows, the
intracellular proteins are synthesized as pre-promature com-
plex in polysomes and prepart is removed cotranslationally,
and then the promature parts are translocated into Golgi-
apparatus,andthenglycosylatedbymannose-richsugar.The
glycosylatedmaturepartistranslocatedintotargetorganelles
and the degradation was started by the splitting from the
ordered nicked bonds to make hydrophobic peptides. These
hydrophobic peptides are secreted to cytoplasm and are
incorporated into the phagosomes or proteosomes after
ubiquitination.
Biological merit of post-translational processing [1]a n d
modiﬁcations of proteins are Possible considerations. The
capability to take variable forms on the way of biosynthesis is
important to keep adaptability to the changing of biological
requirements and intracellular translocation during the
maturation must be regulated. Active enzyme amount must
be regulatable. Pro-parts or bound sugar are the targeting
signals in some cases. In the cases of carbamoyl phosphate
synthetase (CPS) and ornithine transcarbamylase (OTC),
their pro-parts play the role of signals to be recognized by
their receptors located on target organella membrane, such
as lysosomes, as shown in Figure 4.2 Journal of Signal Transduction
Table 1: Half-lives and content of cathepsins by E-64 administrations.
Half-lives (h) Content in lysosomes
(mg/mg protein)
Cathepsin B 14 50 330 920
Cathepsin H 14 30 280 600
Cathepsin L 24 100 105 510
(Control) (E-64) (Control) (E-64)
Table 2: Secretion proﬁles of cathepsins from various cells.
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Figure 1: Common process of post-translational proteins in
general.
The glycosylated cathepsins are targeted into lysosomes
mediated by mannose-6 phosphate receptors which are
located on the lysosomal.
2.Cathepsins
2.1.Cathepsins,suchasB,H,andLAreLocatedintheDiﬀerent
Lysosomes [2, 3]. As Figures 4(a) and 4(b) show, The
lysosomes in which cathepsin H or B is located are attached
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Figure 2:Post-translationalprocessingandmodiﬁcationofcathep-
s i nL ,B ,a n dH .
tothecell-membrane.Onthecontrary,cathepsinLislocated
in the lysosomes which are distributed diﬀusely in liver cells.
As Figure 4(a) shows, using immunodouble gold-particle
staining, cathepsin B (small gold particle) and cathepsin H
(large gold particle) are located clearly in diﬀerent lysosomes
[4]. These diﬀerent localizations are important aspect of
functional share of the diﬀerent cathepsins.Journal of Signal Transduction 3
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Figure 3: Comparison of total amino acids sequences of cathepsins L, H, B, and Papain. (Common sequences are the entrenched circles)
and (Dark-background parts are pro-parts).
2.2. Post-Translational Processing and Maturation of Cathep-
sins L, B, and H [5]. Post-translational processing and
maturation are summarized in Figure 2 [6–8].
Cathepsin L is translated as 17 amino acids of prepart, 96
amino acids of pro-part and 221 amino acids of mature-part
[9, 10]. The prepart is removed cotranslationally and formed
procathepsin is translocated into Golgi-apparatus, and then
the108-Asnandthe155-Asninmaturepartsareglycosylated
by high-mannose-type sugar, as shown in Figure 2(a).T h e
initiation ofthedegradation isstartedfromthenicking bond
(178 bond) cleavage by some cysteine protease [7].
Cathepsin B [11] is translated as 17 amino acids of
prepart, 62 amino acids of pro-part, and 252 amino acids of
mature part [12, 13]. The prepart is also removed cotransla-
tionally and the formed procathepsins are translocated into
Golgi-apparatus and then the 38th-Asn in pro part and
the 111th-Asn in the mature-part are glycosylated by high-
mannose-type sugar.
Thenthemannose-6-phosphate-moitiesplayaroleasthe
targeting marker to the lysosomes. The pro-part was cleaved
oﬀ to make mature cathepsins in the lysosome. The cleavage
ordered nicking at 47th bond was starting to be degraded.
Cathepsin H is translated as 21 amino acids of prepart
[14], 114 amino acids of pro-part, and 217 amino acids of
maturepart.Thepro-parthastwocarbohydratechainsatthe
70th-Asn and the 90th-Asn and the mature part consisted
of 217 amino acids, and one carbohydrate chain is bound at
the 99th-Asn [8, 15]. The initiation of degradation is started
from the 177th nicking bond by cysteine protease.
2.3. Turnover of Cathepsins [17]. Intracellular protein degra-
dation (=autophagosome formation) is regulated by nutri-
tional and hormonal conditions. Fasting or insulin enrich-
ment caused stimulation of the phagosome formation and
cathepsin L amount are increased; on the contrary, refeed-
ing and glucagon enrichment resulted in the suppression
of phagosome formation and decreasing of cathepsin L
amount.
As you see in Figure 2, cathepsins B, L, and H have
individual ordered nicking bond as the initiation of their
degradations; these bonds are cleaved by cysteine protease,
therefore as Table 1 shows, the half-lives (t1/2) of cathepsins
and the contents in lysosomes clearly increased by treatment
by E-64 (inhibitor for all cysteine proteases).
The initiations of degradation of cathepsins are started
from the ordered limited proteolysis by cysteine protease in
the lysosomes, as Figure 2 shows. The formed hydrophobic
products were translocated into autophagosome or protea-
some (after ubiquitinated) to degrade to amino acids.
2.4. Secretion of Cathepsins and Pathogenesis of the Secreted
Cathepsins. Procathepsins or mature cathepsins are secreted4 Journal of Signal Transduction
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Figure 4: Characteristic localization in hepatocytes of cathepsins B, H, and L. (Rat liver) (a) Immuno-gold-particle staining of cathepsin
B and H. (b) From head to down order, B, H, and L. (c) Cathepsin bound mannose-rich sugar compositions. Binding to M6P-Receptor
binding.
Table 3: Composition of bond sugars in cathepsin B [14].
⎛
⎝38 Asn
binding
⎞
⎠ Man
a-1 −→ 6M a n b1 −→ 4GlcNAcb1 −→ 4GlcNAc Fue a1 −→ 6 26%
⎛
⎝111 Asn
binding
⎞
⎠
Man
a-1 −→ 6M a n b1 −→ 4GlcNAcb1 −→ 4GlcNAc 10%
Man
a-1 −→ 6M a n b1 −→ 4GlcNAcb1 −→ 4GlcNAc 3.3%
Man
a-1 −→ 3M a n b1 −→ 4GlcNAcb1 −→ 4GlcNAcJournal of Signal Transduction 5
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Figure 5: Bone resorption by osteoclastic cells, roles of secreted
cathepsin K, and K mediated by ATP proton pomp.
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Figure 6: Roles of pro-part as a signal peptide of mitochondrial
speciﬁc target receptors during the maturation of CPS and OTC in
mitochondria.
from the various cells and play individual physiological, or
pathological roles.
As Figure 5 shows, bone metabolism is consisted of
functional balances between osteoblastic cell function and
osteoclastic cell function.
Bone collagen is degraded mainly by cathepsin L and
K, therefore they are called collagenolytic cathepsins. The
secretion of these cathepsins from osteoclasts is stimulated
by PHT (Parathyroid Hormone) and suppressed by vitamin
D3, E-64, CA-148 eta. Therefore, bone metastasis of cancers
is inhibited by cathepsin inhibitors, such as by E-64 or CLIK-
148 [18].
Cystatin α in epidermis
A
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INS
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Figure 7: (a) Cystatin α (phosphorylated cystatin α) is localized
in keratohyalin granules, (B) the treatment of protein C kinase
inhibitor H7. No targeting of cystatin α in granules was observed.
(A), (b) The localization of cystatin β.C y s t a t i nβ is localized and
co-localized with insulin secretary granules.
As Pit formation test in Table 4 shows, bone-matrix
degradation is catalyzed by cathepsin L, but not by cathepsin
B.
3.Cystatins
Endogenous low-molecular weight cathepsin inhibitors are
consisted of two big groups [19] ,o n ei so n l yl o c a t e di n
skin and the other is ubiquitously located in all organs [16].
Cystatin α (A) [20] is only located in epidermis, cystatin β
(B) [21] is located ubiquitously in all cells (organs) [22]. The
secretary formed cystatins are Cystatin C in eggwhite and
cystatin S in the saliva. γ-trace is secreted from cerebrospinal6 Journal of Signal Transduction
Cystatin β
Papain
Figure 8: X-ray crystallography structure-binding complex
between cystatin β and papain.
Table 4: Contribution of cathepsin L or B on bone resorption.
Inhibitors
(10−6M)
Cathepsin
L
Cathepsin
B
Bone
resorption
Control 100 100 100 %
Pepstatin − 103 104 104 %
CA-074 − 100 2.2 94 %
E-64 + 10 2 40 %
Cystatin α +3 . 14 . 31 8%
Chymostatin + 9.8 101 6 %
CA-148 + 0 100 0 %
Table 5: Organ distributions of cystatin α and β [16].
Organs Cystatin α Cystatin β
(ng/mg protein)
Epidermis 2800 320
Kidney 0.5 200
Liver 0.2 230
Brain 0.3 310
Muscle 0.3 76
Margen 820 420
ﬂuid.Anothersecretarygrouphavinghigh-molecularweight
(repeated low molecular cystatins) is kininogen family in
serum [22].
Each cystatin shows diﬀerent inhibitory speciﬁcity for
individual cathepsins, for example, cystatin α does not
inhibit cathepsin B activity but strongly inhibit cathepsin L
activity and cathepsin H activities [7, 19]. This is important
as their function shares against cathepsin family.
M
M
M
M
M
M
M
M
M M
T
T T
EY
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
KL
L
L
L L L
L
L
L
L
LL
L
L
L
L
L
L
L
L
L
L
L
V
V
V
V
V
V
V
V
V V
VV
V
V
V
V
V
V
V
V
V V
V V
VV V G
GG
G
G
G
G
G
G
G
G
G
G
G
GG
G G
G G
G
G
G
G G
G
G
G
G
GG K
K
K
K
KK
KK
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
S
S
S
S
SS
S
S
S
SS
S S
SS
S
S
S
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A A
A
A
A
A
AA
A
A
A
A
A
A
A
LT
T T
T
T
-
-
-- - - -
-
--- ----- -
- -
--
-
- -
-
I
I
I
I
I
I
I
I
I
I
I
I
I I
I
I
I I
I
II
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
Q
V
V
V
VV
V
V
V
V
VV
V
VV Q
VV Q
V Q
V Q
V Q
CP
P
P
PP P
P
PP
P
P
P
P P
E
E
E
E
E E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
E
T
T D
D
DD
D
D
D
DD D
D
D
D
D
D
D
G V D
D D
D
D
D
R
R
R
R
R
RR
R R
R R
R
R
R
R R
R
R
R
R
R
R
R
YN
N
N
N
N
N
N
N
N
N
N
N
N
N
W
HF
F
F
F
FF
F F
F
FF
F
F
F
T
T
T
T
TT
T
T
T
T
T
T
T
H
H
C
C
C
C
C
(1)
(2)
(3)
(4)
(5)
(6)
(1)
(2)
(3)
(4)
(5)
(6)
(1)
(2)
(3)
(4)
(5)
(6)
cHa-ras
Cystatin β 
Cystatin α 
Cystatin C 
Cystatin S 
Cystatin clostridium 
Y
(a)
M
MM
Y
Y
Y L
L
LL L L L L
L
G
G
G
G
G
G
G G
G K
K
K
K
K
KK
K
K
K KK K
S
S
S
A A
A
A I I
I
Q
Q
Q
Q
Q
V
V
VV
V
V
V
V
V V
P P PE
E
E E
E
E
E EE
D
D
D
D
D
D
DD D
R
R
R
N F
T
T
T T
TT A c -------- ------------- -----
---
- - --
- - --- - -- - - - - - - - - - - - - - - - - -
--
-
--- --------------- ---
------------ - ----------
H F FN
N N
TF
10 20
40 30
60
80
50
100
90
70
92
P
(b)
Figure 9: (a) Sequence homology of cystatin family. (b) Phospho-
rylatedcystatina.ThetargetingsignalofincorporationofP-cystatin
α into corniﬁed envelop. (The 92th-Theonine residue).
3.1. Post-Translational Processing of Cystatins. The amino-
acid sequences of low-molecular weight cystatin family
have strong homology, however, their post-translational
processing are quite diﬀerent. Because their localizations and
biological functions is quite diﬀerent.Journal of Signal Transduction 7
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Figure 10: Post-translational modiﬁcations of cystatin α-
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Figure 11: Functional modiﬁcation of cystatin β with glutathione
by disulfate-bond formation.
3.1.1. Cystatin α [23–25]. When skin was stained by
immunohistochemistry using anticystatin α antibody, only
the corniﬁed-envelope of skin was stained [16]. The sph-
ingosine treatment to new born skin resulted in the strong
suppression of the targeting of cystatin α into the corniﬁed
envelope. The sphingosine is a powerful inhibitor for protein
kinase C. As shown in Figures 7(a) and 7(b), threonine
residue in near C-terminus (the 92th threonine in Figure 9
shows) of cystatin α is phosphorylated by protein kinase
C, and the phosphorglated cystatin α is incorporated into
corniﬁed envelope. The participation of protein kinase C in
the phosphorylation of cystatin α was also conﬁrmed using
speciﬁcinhibitorofproteinkinaseC,(HidakaH-7)inhibited
the incorporation of P32 into cystatin α.
The phosphorylated cystatin α was incorporated into
skin corniﬁed envelop. In the envelop, the phosphorylated
cystatin α was conjugated with ﬁlaggrin-linker sediment
peptide which is rich in glutamine residues, mediated by
epidermal transglutaminase in the presence of calcium, and
yield a high-molecular weight protein (skin ﬁber), as shown
in Figure 10.
The phosphorylated cystatin α showed strong inhibition
to cathepsin L, but not to the cathepsin B and H, it
also showed strong inhibition to the bacterial cysteine
proteases and virus cathepsins. Therefore, cystatin α and
phosphorylated cystatin α showed strong protection from
infections of bacteria or viruses in skin.
3.1.2. Cystatin β [26, 27]. Post-translational covalent mod-
iﬁcation of cystatin β and the changing of their inhibitory
activities. Cystatin β is located ubiquitously in lysosomes
of various organs. The third position of the N-termius-
cysteine residue of cystatin β reacts with glutathione to
form a mixed disulfate complex and also is able to make
dimmer by the disulfate bond. Those are inactive forms. As
Figure 8 shows, N-terminus of cystatins was inserted into the
substrate binding pocket of cathepsins, the glutathionated
or the dimmer form were unable to insert into the binding
pocket of cathepsins.The coeﬃcient of oxidized or reduced
forms of glutathiones regulates the inhibitory activity of
cystatinβ.Therefore,theactivitiesofcathepsinsareregulated
by the intracellular redox potentials in spite of the changes of
the inhibitory activities of cystatin β.
As Figure 7(b) shows, using β-cell of pancreas, the
cystatin β is located in insulin secretion particles, therefore,
cystatin β is secreted with insulin in the pancreas.
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